Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Shares Outstanding (Weighted Average) (2018 - 2025)

Summit Therapeutics (SMMT) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $741.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) rose 2.03% year-over-year to $741.4 million, compared with a TTM value of $741.4 million through Sep 2025, up 2.03%, and an annual FY2024 reading of $718.5 million, up 15.96% over the prior year.
  • Shares Outstanding (Weighted Average) was $741.4 million for Q3 2025 at Summit Therapeutics, roughly flat from $742.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $742.6 million in Q2 2025 and bottomed at $131.7 million in Q4 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $549.5 million, with a median of $660.7 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 266.01% in 2023, then rose 2.03% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $131.7 million in 2021, then surged by 46.78% to $193.3 million in 2022, then skyrocketed by 220.5% to $619.6 million in 2023, then increased by 15.96% to $718.5 million in 2024, then increased by 3.18% to $741.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for SMMT at $741.4 million in Q3 2025, $742.6 million in Q2 2025, and $738.1 million in Q1 2025.